

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1.-6. (Cancelled)

7. (Currently amended) A composition comprising a plurality of nucleic acid molecules, wherein the nucleic acid molecules comprise nucleotide sequences encoding different human cytomegalovirus (HCMV) polypeptides that induce a neutralizing antibody response, wherein the HCMV polypeptides comprise[[:]] glycoprotein M (gM), or an antigenic fragment of gM, and glycoprotein N (gN), or an antigenic fragment of gN; wherein the nucleic acid molecules comprise DNA plasmids.

8. (Currently Amended) The composition of claim 7, wherein the HCMV polypeptides that induce an antibody response consist of[[:]] gM or an antigenic fragment thereof; and gN or an antigenic fragment thereof.

9-17. (Canceled)

18. (Original) A pharmaceutical composition that elicits an immune response against human cytomegalovirus (HCMV) comprising the composition of claim 7 and a pharmaceutically acceptable carrier.

19. (Canceled)

20. (Withdrawn, currently amended) A method of eliciting an immune response against human cytomegalovirus (HCMV) in a subject, the method comprising administering to the subject an amount of a pharmaceutical composition of claim ~~47~~ 18 effective to elicit an immune response against HCMV in the subject.

21. (Withdrawn) The method of claim 20, wherein administration is by needle injection, needle-less jet injection, gene gun, topical administration, surgical administration, or mucosal administration.

22. (Withdrawn) The method of claim 20, wherein the subject is a non-human mammal or a human.

23. (Withdrawn) The method of claim 22, wherein the human is sero-negative for HCMV.

24. (Withdrawn) The method of claim 23, wherein the sero-negative human is selected from the group consisting of a female between the ages of eleven and forty, a female contemplating pregnancy, a pregnant female, an HIV-infected individual, a future organ transplant recipient, and a future bone marrow donor.

25. (Withdrawn) The method of claim 22, wherein the human is sero-positive for HCMV.

26. (Withdrawn, currently amended) A kit comprising the composition of claim [[1]] 7 and instructions for administration of the composition to a subject in an amount effective to treat a CMV infection.

27. (Withdrawn) The kit of claim 26, wherein the amount is effective to inhibit a future CMV infection.

28. (Withdrawn) The kit of claim 26, wherein the amount is effective to treat an existing CMV infection.

29. (Withdrawn) The kit of claim 26, wherein the composition comprises DNA plasmids.

30-32. (Withdrawn)

33. (Previously presented) The composition of claim 7, wherein the composition comprises a plurality of sets of nucleic acid molecules, each set of nucleic acid molecules encoding a different HCMV polypeptide, and each molecule of a set encoding the same HCMV polypeptide.

34-37. (Canceled)

38. (New) The composition of claim 7, wherein the composition comprises a plurality of sets of nucleic acid molecules, each set of nucleic acid molecules encoding at least two different HCMV polypeptides, and each molecule of a set encoding the same HCMV polypeptides.

39. (New) The composition of claim 7, wherein the HCMV polypeptides further comprise glycoprotein B (gB), or an antigenic fragment thereof.